Pharma Pulse: FDA Approval of Icotyde for Plaque Psoriasis and CCT’s MedAssure Debut
Mar 19, 10:00 AM
Share
Subscribe
In today's Pharma Pulse, the FDA approves Icotyde as the first targeted oral
peptide therapy for moderate-to-severe plaque psoriasis, while Cold Chain Technologies prepares to debut its MedAssure orchestration platform at LogiPharma 2026